Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.45 |
| ▸ | MELK | Q14680 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7959593 | 0.81 | EGFR (0.51) | EGFRFGFR4MELKALDH1A1PIK3CD | |
| SCHEMBL7796162 | 0.72 | EGFR (0.63) | EGFRFGFR4MELKALDH1A1PDGFRB | |
| SCHEMBL737948 | 0.72 | EGFR (0.55) | EGFRFGFR4ALDH1A1PIK3CDPIK3CA | |
| SCHEMBL2011007 | 0.72 | EGFR (0.55) | EGFRFGFR4ALDH1A1PIK3CDPIK3CA | |
| SCHEMBL30618089 | 0.72 | EGFR (0.55) | EGFRFGFR4PIK3CDPIK3CA | |
| SCHEMBL3393275 | 0.72 | EGFR (0.55) | EGFRFGFR4PIK3CDPIK3CA | |
| SCHEMBL30853054 | 0.72 | EGFR (0.55) | EGFRFGFR4PIK3CDPIK3CA | |
| Hydrochloric Acid SCHEMBL30376208 | 0.70 | EGFR (0.53) | EGFRFGFR4PIK3CDPIK3CA | |
| SCHEMBL27788810 | 0.70 | EGFR (0.53) | EGFRFGFR4PIK3CDPIK3CA | |
| SCHEMBL7962437 | 0.69 | EGFR (0.42) | EGFRFGFR4PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194596-A1 | Therapeutic Combination Including a Selective Erbb2 Inhibitor | FRIZER INC. | 2008-08-14 | — | — | US | disclosed |
| US-20050101618-A1 | Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer | PFIZER INC | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101618-A1 | Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer | ERBB2, ERBB3, EGFR | EGFR 3/4885FGFR4 17/4885MELK 214/4885 |
| US-20080194596-A1 | Therapeutic Combination Including a Selective Erbb2 Inhibitor | ERBB2, ERBB3, EGFR | EGFR 3/4885FGFR4 47/4885MELK 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.